| Identification | Back Directory | [Name]
1-Piperazinedodecanamide, 4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-N-[2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]ethyl]-λ-oxo- | [CAS]
2523016-96-6 | [Synonyms]
SK-575
1-Piperazinedodecanamide, 4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-N-[2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]ethyl]-λ-oxo- | [Molecular Formula]
C47H53FN8O8 | [MOL File]
2523016-96-6.mol | [Molecular Weight]
876.99 |
| Chemical Properties | Back Directory | [density ]
1.40±0.1 g/cm3(Predicted) | [solubility ]
DMSO:87.7(Max Conc. mg/mL);100.0(Max Conc. mM) | [form ]
Solid | [pka]
10.74±0.40(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Description]
SK-575 is a Highly Potent and Efficacious Proteolysis-Targeting Chimera Degrader of PARP1 for Treating Cancers. SK-575 potently inhibits the growth of cancer cells bearing BRCA1/2 mutations and induces potent and specific degradation of PARP1 in various human cancer cells even at low picomolar concentrations. SK-575 achieves durable tumor growth inhibition in mice when used as a single agent or in combination with cytotoxic agents, such as temozolomide and cisplatin. | [storage]
Store at -20°C |
|
|